A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
Open Access
- 1 April 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 10 (2) , 208-215
Abstract
To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of inKeywords
This publication has 18 references indexed in Scilit:
- Neoplastic meningitis-related encephalopathyNeurology, 2004
- Phase I Clinical Trial of Intrathecal Topotecan in Patients With Neoplastic MeningitisJournal of Clinical Oncology, 2003
- An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic MeningitisJournal of Neuro-Oncology, 2002
- Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabineBritish Journal of Cancer, 2001
- A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.1999
- Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous MeningitisJournal of Clinical Oncology, 1999
- Leptomeningeal CarcinomatosisArchives of Neurology, 1996
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI: Journal of the National Cancer Institute, 1992
- Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumorsCancer Chemotherapy and Pharmacology, 1992
- Meningeal carcinomatosis from breast cancer: Spinal cord vs. brain involvementBreast Cancer Research and Treatment, 1987